Leuprolide Acetate is the acetate salt of a synthetic nonapeptide analog of the gonadotropin-releasing hormone. A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE that regulates the synthesis and release of pituitary gonadotropins, LUTEINIZING HORMONE, and FOLLICLE STIMULATING HORMONE. Leuprolide binds to and activates gonadotropin-releasing hormone (GnRH) receptors. Continuous, prolonged administration of leuprolide in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. This agent reduces testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression.
Leuprolide acetate is an acetate salt obtained by combining the nonapeptide leuprolide with acetic acid. A long-lasting GnRH analog, LH-Rh agonist. It is a synthetic nonapeptide analog of gonadotropin-releasing hormone and is used as a subcutaneous hydrogel implant for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty. It has a role as an antineoplastic agent and a gonadotropin-releasing hormone agonist. It contains leuprolide.
Leuprolide is a synthetic 9-residue peptide analog of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[rx,rx]
Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename Lupron by Abbvie Endocrine Inc.[rx] Since this initial approval, various long-acting intramuscular and subcutaneous products have been developed such that patients can be dosed once every six months.[rx,rx] Leuprolide remains frontline therapy in all conditions for which it is indicated for use.
Mechanism of Action
Like naturally occurring luteinizing hormone-releasing hormone, initial or intermittent administration of leuprolide stimulates the release of luteinizing hormone and follicle-stimulating hormone from the anterior pituitary.
Gonadotropin-releasing hormone (GnRH) is a naturally occurring decapeptide that modulates the hypothalamic-pituitary-gonadal (HPG) axis. GnRH binds to corresponding receptors (GnRHRs) on the anterior pituitary gonadotropes, which in turn release luteinizing hormone (LH) and follicle-stimulating hormone (FSH); these, in turn, affect the downstream synthesis and release of the sex hormones testosterone, dihydrotestosterone, estrone, and estradiol.[rx]
Despite the variety of conditions indicated for treatment with leuprolide, the mechanism of action underlying efficacy is the same in all cases. As a GnRHR agonist, leuprolide binds to and initially activates downstream LH and FSH release; this initial spike in gonadotropin levels is responsible for some of the adverse effects associated with treatment. After 2-4 weeks of treatment, continuous stimulation of GnRHR results in feedback inhibition and significant downregulation of LH, FSH, and their corresponding downstream effects, producing a therapeutic benefit. These effects are reversible upon treatment discontinuation
Luteinizing hormone and follicle-stimulating hormone release from the anterior pituitary transiently increase testosterone concentration in males. However, continuous administration of leuprolide in the treatment of prostatic carcinoma suppresses the secretion of gonadotropin-releasing hormone, with a resultant fall in testosterone concentrations and a “medical castration”.
Initial stimulation of gonadotropins from the anterior pituitary is followed by prolonged suppression. Gonadotropin release from the anterior pituitary transiently increases estrone and estradiol concentrations in females. However, continuous administration of leuprolide in the treatment of endometriosis produces a fall in estrogens to postmenopausal levels. As a consequence of the suppression of ovarian function, both normal and ectopic endometrial tissues become inactive and atrophic. As a result, amenorrhea occurs.
Indications
- Antineoplastic Agents, Hormonal; Fertility Agents, Female. Leuprolide is indicated for the palliative treatment of advanced prostatic cancer, especially as an alternative to orchiectomy or estrogen administration.
- Leuprolide is a peptide-based GnRH receptor superagonist used for the palliative treatment of prostate cancer, uterine leiomyomata, endometriosis, and central precocious puberty.
- Leuprolide is indicated for the treatment of advanced prostate cancer and as a palliative treatment of advanced prostate cancer. It is also used for the treatment of pediatric patients with central precocious puberty (CPP). In combination with oral norethisterone (also known as norethindrone), leuprolide is also indicated for the initial treatment of the symptoms of endometriosis.[rx] Finally, in combination with iron supplementation, leuprolide is indicated for the preoperative hematological improvement of anemic patients with uterine leiomyomata (uterine fibroids).[rx]
- Advanced Prostate Cancer
- Anemia
- Central Precocious Puberty (CPP)
- Endometriosis
Leuprolide is indicated for the management of endometriosis, including pain relief and reduction of endometriotic lesions. Leuprolide is about 30 times more active than natural gonadotropin-releasing hormone … and 100 times more active than gonadorelin.
Contraindications
- spread of cancer to the spinal column
- diabetes
- high cholesterol
- low amount of magnesium in the blood
- low amount of potassium in the blood
- overweight
- depression
- high blood pressure
- a heart attack
- prolonged QT interval on EKG
- chronic heart failure
- abnormal EKG with QT changes from birth
- a stroke
- liver problems
- decreased calcification or density of bone
- seizures
- pregnancy
- obstruction of any part of the urinary tract
- tobacco smoking
Dosage
Strengths: 7.5 mg/month; 22.5 mg/3 months; 45 mg/6 months; 30 mg/4 months; 65 mg; 11.25 mg/month; 15 mg/month; 3.75 mg/month; 11.25 mg/3 months; 30 mg/3 months; 5 mg/mL; 1 mg/0.2 mL; 7.5 mg; 3.75 mg; 42 mg/6 months.
Prostate Cancer
IM: LUPRON DEPOT:
- 7.5 mg IM once a month OR
- 22.5 mg IM every 3 months OR
- 30 mg IM every 4 months OR
- 30 mg IM every 6 months
IMPLANT:
VIADUR IMPLANT:
- 65 mg inserted subcutaneously in the inner aspect of the upper arm every 12 months
SUBCUTANEOUS:
CAMCEVI:
- 42 mg subcutaneously every 6 months
ELIGARD:
- 7.5 mg subcutaneously once a month OR
- 22.5 mg subcutaneously every 3 months OR
- 30 mg subcutaneously every 4 months OR
- 45 mg subcutaneously every 6 months
- Treatment is usually continued in patients who are treated with gonadotropin-releasing hormone (GnRH) analogs and who develop non-metastatic and metastatic castration-resistant prostate cancer.
- Implant: The manufacturer’s product information should be consulted regarding insertion and removal techniques.
- Palliative treatment of advanced prostate cancer
- Treatment of advanced prostate cancer
Endometriosis
IM: Endometriosis:
LUPRON DEPOT 3.75 mg:
- Initial treatment: 3.75 mg IM once a month for up to 6 months
- Retreatment: 3.75 mg IM once a month for 1 to 6 months
- Duration of treatment: Up to 12 months
OR
- LUPRON DEPOT 11.25 mg: 11.25 mg IM every 3 months
- Duration of treatment: Up to 12 months
Uterine Leiomyomata
- 3.75 mg IM once a month OR
- 11.25 mg IM once
- Limitation of use: In women receiving this drug for endometriosis, the total duration of treatment with this drug and add-back hormone replacement therapy (norethindrone 5 mg) should be limited to 12 months to reduce bone mineral density loss and vasomotor symptoms.
- Limitation of use: This drug has not been approved for use with norethindrone for the preoperative improvement of patients with anemia caused by heavy bleeding due to fibroids.
- Management of endometriosis (including pain relief and reduction of endometriotic lesions)
- With norethindrone for the initial management of endometriosis symptoms and for the management of recurrent symptoms
- Preoperative hematologic improvement of patients with anemia caused by uterine leiomyomata/fibroids
Uterine Leiomyomata
IM: Endometriosis
LUPRON DEPOT 3.75 mg
- Initial treatment: 3.75 mg IM once a month for up to 6 months
- Retreatment: 3.75 mg IM once a month for 1 to 6 months
- Duration of treatment: Up to 12 months OR LUPRON DEPOT 11.25 mg: 11.25 mg IM every 3 months
- Duration of treatment: Up to 12 months
Uterine Leiomyomata
- 3.75 mg IM once a month OR 11.25 mg IM once
- Limitation of use: In women receiving this drug for endometriosis, the total duration of treatment with this drug and add-back hormone replacement therapy (norethindrone 5 mg) should be limited to 12 months to reduce bone mineral density loss and vasomotor symptoms.
- Limitation of use: This drug has not been approved for use with norethindrone for the preoperative improvement of patients with anemia caused by heavy bleeding due to fibroids.
- Management of endometriosis (including pain relief and reduction of endometriotic lesions)
- With norethindrone for the initial management of endometriosis symptoms and for the management of recurrent symptoms
- Preoperative hematologic improvement of patients with anemia caused by uterine leiomyomata/fibroids
Pediatric Dose for Precocious Puberty
2 years and older:
IM INJECTION: 1-MONTH DEPOT INJECTION:
- 25 kg or less: 7.5 mg IM once a month
- Greater than 25 kg to 37.5 kg: 11.25 mg IM once a month
- Greater than 37.5 kg: 15 mg IM once a month
3-MONTH DEPOT INJECTION
- 11.25 or 30 mg IM every 3 months
- Doses should be titrated to the individual.
- Hormone levels should be tested after 1 to 2 months (for 1-month injections) OR after 2 to 3 months (for 3-month injections) of therapy and with each dose change to ensure adequate pituitary gonadotropin suppression.
- Once a dose that results in adequate hormonal suppression has been determined, it can often be maintained for the duration of therapy in most children; however, hormonal suppression should be verified as weight can increase significantly while on therapy.
- Therapy should be discontinued at the appropriate age of onset of puberty at the discretion of the physician.
SUBCUTANEOUS INJECTION:
- Fensolvi: 45 mg subcutaneously every 6 months
- NOTE: The short-acting formulation has been replaced with long-acting formulations.
- The dosage should be adjusted for weight changes.
- Discontinuation of therapy should be considered at the appropriate age for the onset of puberty.
- Central precocious puberty (CPP) is defined as the early onset of secondary sexual characteristics (generally earlier than 8 years in girls and 9 years in boys) associated with pubertal pituitary gonadotropin activation; it may show a significantly advanced bone age that can result in diminished adult height.
Dose Adjustments
- Pediatric patients: If adequate hormonal and clinical suppression is not reached with the starting dose, it should be increased to the next available higher dose (e.g., 11.25 mg or 15 mg at the next monthly injection).
Administration advice:
- The injection site should be varied periodically.
- Avoid areas with brawny or fibrous subcutaneous tissue or locations that could be rubbed or compressed (e.g., with a belt or clothing waistband)
- The manufacturer’s product information should be consulted.
Side Effects
The Most Common
- tiredness
- hot flashes (a sudden wave of mild or intense body heat), sweating, or clamminess
- breast tenderness, pain, or change in breast size in both men and women
- vaginal discharge, dryness, or itching in women
- spotting (light vaginal bleeding) or menstruation (periods)
- decrease in the size of testicles
- decrease in sexual ability or desire
- swelling of the hands, feet, ankles, or lower legs
- pain, burning, or tingling in the hands or feet
- pain, burning, bruising, redness, or hardening at the place where the injection was given
- change in weight
- muscle or joint pain
- runny nose, cough, sore throat, or flu-like symptoms
- fever
- stomach pain
- constipation
- headache
- acne
- depression
- unable to control emotions and frequent mood changes
- nervousness
- a general feeling of discomfort or uneasiness
- difficulty with memory
- itching, rash, or hives
- difficulty breathing or swallowing
- pain in the arms, back, chest, neck, or jaw
- slow or difficult speech
- dizziness or fainting
- weakness, numbness, or inability to move an arm or leg
- bone pain
- painful, frequent, or difficult urination
- blood in urine
- extreme thirst
- weakness
- dry mouth
- nausea
- vomiting
- breath that smells fruity
- decreased consciousness
- sudden headache
- blurred vision
- vision changes
- difficulty moving eyes
- drooping eyelids
- confusion
- seizures
MORE COMMON
- Arm, back, or jaw pain
- bloody or cloudy urine
- blurred vision
- bone pain
- chest pain or discomfort
- difficult, burning, or painful urination
- difficulty with moving
- dizziness
- frequent urge to urinate
- headache
- increased urge to urinate during the night
- muscle pain or stiffness
- nausea
- nervousness
- pain in the arms or legs
- pain in the joints
- pale skin
- pounding in the ears
- slow or fast heartbeat
- sweating
- unusual bleeding or bruising
- unusual tiredness or weakness
- waking to urinate at night
- burning, numbness, tingling, or painful sensations
- chest pain
- cold, clammy, pale skin
- confusion
- dizziness or lightheadedness
- double vision
- dry mouth
- flushed, dry skin
- fruit-like breath odor
- increased hunger
- increased thirst
- increased urination
- irregular heartbeat
- loss of consciousness
- seizures
- thoughts or attempts at killing oneself
- unexplained weight loss
- unsteadiness or awkwardness
- visual changes
- weakness in the arms, hands, legs, or feet
- Anxiety
RARE
- Pain in the groin or legs (especially in the calves)
- Altered mental status
- anxiety
- blurred vision
- deepening of voice
- increased hair growth
- mental depression
- mood changes
- Body aches or pain
- chest tightness
- chills
- cough
- cough producing mucus
- difficulty in breathing
- ear congestion
- fever
- headache
- loss of voice
- muscle aches
- noisy breathing
- pain or redness at the injection site
- runny or stuffy nose
- sneezing
- sore throat
- unusual tiredness or weakness
- Irritability
- mood or mental changes
- Burning, itching, or swelling at the injection site
- Blurred vision
- change in ability to see colors, especially blue or yellow
- nausea and vomiting
- seizures
- severe headache
Drug Interaction
| DRUG | INTERACTION |
|---|---|
| Abacavir | Leuprolide may decrease the excretion rate of Abacavir which could result in a higher serum level. |
| Acarbose | The therapeutic efficacy of Acarbose can be decreased when used in combination with Leuprolide. |
| Aceclofenac | Aceclofenac may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Acemetacin | Acemetacin may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Acetaminophen | Leuprolide may decrease the excretion rate of Acetaminophen which could result in a higher serum level. |
| Acetazolamide | Acetazolamide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Acetohexamide | The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Leuprolide. |
| Acetylsalicylic acid | Acetylsalicylic acid may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Acipimox | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Acipimox. |
| Aclidinium | Leuprolide may decrease the excretion rate of Aclidinium which could result in a higher serum level. |
| Acrivastine | The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Leuprolide. |
| Acyclovir | Acyclovir may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Adefovir dipivoxil | Adefovir dipivoxil may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Adenosine | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Adenosine. |
| Ajmaline | The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Leuprolide. |
| Albiglutide | The therapeutic efficacy of Albiglutide can be decreased when used in combination with Leuprolide. |
| Albutrepenonacog | Leuprolide may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level. |
| Alclofenac | Alclofenac may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Aldesleukin | Leuprolide may decrease the excretion rate of Aldesleukin which could result in a higher serum level. |
| Alendronic acid | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Alendronic acid. |
| Alfuzosin | The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Leuprolide. |
| Alimemazine | The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Leuprolide. |
| Allopurinol | Leuprolide may decrease the excretion rate of Allopurinol which could result in a higher serum level. |
| Almasilate | Leuprolide may decrease the excretion rate of Almasilate which could result in a higher serum level. |
| Almotriptan | Leuprolide may decrease the excretion rate of Almotriptan which could result in a higher serum level. |
| Alogliptin | The therapeutic efficacy of Alogliptin can be decreased when used in combination with Leuprolide. |
| Alprazolam | Leuprolide may decrease the excretion rate of Alprazolam which could result in a higher serum level. |
| Amantadine | The risk or severity of QTc prolongation can be increased when Amantadine is combined with Leuprolide. |
| Amifampridine | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Amifampridine. |
| Amikacin | Leuprolide may decrease the excretion rate of Amikacin which could result in a higher serum level. |
| Amiloride | Amiloride may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Aminophenazone | Aminophenazone may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Amiodarone | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Amiodarone. |
| Amisulpride | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Amisulpride. |
| Amitriptyline | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Amitriptyline. |
| Ammonium chloride | Leuprolide may decrease the excretion rate of Ammonium chloride which could result in a higher serum level. |
| Amodiaquine | The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Leuprolide. |
| Amoxapine | The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Leuprolide. |
| Amoxicillin | Leuprolide may decrease the excretion rate of Amoxicillin which could result in a higher serum level. |
| Amphetamine | Leuprolide may decrease the excretion rate of Amphetamine which could result in a higher serum level. |
| Amphotericin B | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Amphotericin B. |
| Ampicillin | Leuprolide may decrease the excretion rate of Ampicillin which could result in a higher serum level. |
| Amrinone | Leuprolide may decrease the excretion rate of Amrinone which could result in a higher serum level. |
| Anagrelide | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Anagrelide. |
| Ancestim | Leuprolide may decrease the excretion rate of Ancestim which could result in a higher serum level. |
| Antazoline | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Antazoline. |
| Antihemophilic | Leuprolide may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level. |
| Antipyrine | Antipyrine may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Antithrombin | Leuprolide may decrease the excretion rate of Antithrombin III human which could result in a higher serum level. |
| Antrafenine | Antrafenine may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Apalutamide | Leuprolide may decrease the excretion rate of Apalutamide which could result in a higher serum level. |
| Apomorphine | The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Leuprolide. |
| Apremilast | Leuprolide may decrease the excretion rate of Apremilast which could result in a higher serum level. |
| Arformoterol | The risk or severity of QTc prolongation can be increased when Arformoterol is combined with Leuprolide. |
| Aripiprazole | The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Leuprolide. |
| Aripiprazole lauroxil | The risk or severity of QTc prolongation can be increased when Aripiprazole lauroxil is combined with Leuprolide. |
| Arsenic trioxide | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Arsenic trioxide. |
| Artemether | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Artemether. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Articaine. |
| Asenapine | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Asenapine. |
| Astemizole | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Astemizole. |
| Atazanavir | The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Leuprolide. |
| Atomoxetine | The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Leuprolide. |
| Atorvastatin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Atorvastatin. |
| Atropine | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Atropine. |
| Auranofin | Leuprolide may decrease the excretion rate of Auranofin which could result in a higher serum level. |
| Aurothioglucose | Leuprolide may decrease the excretion rate of Aurothioglucose which could result in a higher serum level. |
| Azacitidine | Leuprolide may decrease the excretion rate of Azacitidine which could result in a higher serum level. |
| Azatadine | The risk or severity of QTc prolongation can be increased when Azatadine is combined with Leuprolide. |
| Azathioprine | Leuprolide may decrease the excretion rate of Azathioprine which could result in a higher serum level. |
| Azelaic acid | Leuprolide may decrease the excretion rate of Azelaic acid which could result in a higher serum level. |
| Azithromycin | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Azithromycin. |
| Aztreonam | Leuprolide may decrease the excretion rate of Aztreonam which could result in a higher serum level. |
| Bacitracin | Bacitracin may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Baclofen | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Baclofen. |
| Balsalazide | Balsalazide may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Baricitinib | Leuprolide may decrease the excretion rate of Baricitinib which could result in a higher serum level. |
| Bedaquiline | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Bedaquiline. |
| Bendroflumethiazide | Bendroflumethiazide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Benorilate | Benorilate may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Benoxaprofen | Benoxaprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Benserazide | Leuprolide may decrease the excretion rate of Benserazide which could result in a higher serum level. |
| Benzatropine | The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Leuprolide. |
| Benznidazole | Leuprolide may decrease the excretion rate of Benznidazole which could result in a higher serum level. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Benzocaine. |
| Benzthiazide | Benzthiazide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Benzydamine | Benzydamine may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Benzyl alcohol. |
| Bepotastine | Leuprolide may decrease the excretion rate of Bepotastine which could result in a higher serum level. |
| Bepridil | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Bepridil. |
| Berotralstat | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Berotralstat. |
| Betamethasone | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Betamethasone. |
| Bezafibrate | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Bezafibrate. |
| Bicisate | Leuprolide may decrease the excretion rate of Bicisate which could result in a higher serum level. |
| Bilastine | The risk or severity of QTc prolongation can be increased when Bilastine is combined with Leuprolide. |
| Bismuth subgallate | Leuprolide may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level. |
| Bisoprolol | Leuprolide may decrease the excretion rate of Bisoprolol which could result in a higher serum level. |
| Bisoxatin | Leuprolide may decrease the excretion rate of Bisoxatin which could result in a higher serum level. |
| Bleomycin | Leuprolide may decrease the excretion rate of Bleomycin which could result in a higher serum level. |
| Bortezomib | The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Leuprolide. |
| Bretylium | The risk or severity of QTc prolongation can be increased when Bretylium is combined with Leuprolide. |
| Brivaracetam | Leuprolide may decrease the excretion rate of Brivaracetam which could result in a higher serum level. |
| Bromazepam | Leuprolide may decrease the excretion rate of Bromazepam which could result in a higher serum level. |
| Bromocriptine | The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Leuprolide. |
| Bromotheophylline | Bromotheophylline may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Brompheniramine | The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Leuprolide. |
| Buclizine | The risk or severity of QTc prolongation can be increased when Buclizine is combined with Leuprolide. |
| Budesonide | Leuprolide may decrease the excretion rate of Budesonide which could result in a higher serum level. |
| Bumadizone | Bumadizone may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Bumetanide | Bumetanide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Bupivacaine. |
| Bupropion | Leuprolide may decrease the excretion rate of Bupropion which could result in a higher serum level. |
| Buserelin | The risk or severity of QTc prolongation can be increased when Buserelin is combined with Leuprolide. |
| Buspirone | Leuprolide may decrease the excretion rate of Buspirone which could result in a higher serum level. |
| Butabarbital | Leuprolide may decrease the excretion rate of Butabarbital which could result in a higher serum level. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Butacaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Butamben. |
| Butriptyline | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Butriptyline. |
| Canagliflozin | The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Leuprolide. |
| Canrenoic acid | Canrenoic acid may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Capecitabine | Leuprolide may decrease the excretion rate of Capecitabine which could result in a higher serum level. |
| Capreomycin | Leuprolide may decrease the excretion rate of Capreomycin which could result in a higher serum level. |
| Capromab pen | Leuprolide may decrease effectiveness of Capromab pendetide as a diagnostic agent. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Capsaicin. |
| Captopril | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Captopril. |
| Carbamazepine | Leuprolide may decrease the excretion rate of Carbamazepine which could result in a higher serum level. |
| Carbidopa | Leuprolide may decrease the excretion rate of Carbidopa which could result in a higher serum level. |
| Carbimazole | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Carbimazole. |
| Carbinoxamine | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Carbinoxamine. |
| Carboplatin | Carboplatin may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Carmustine | Leuprolide may decrease the excretion rate of Carmustine which could result in a higher serum level. |
| Carprofen | Carprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Cefaclor | Cefaclor may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Cefadroxil | Cefadroxil may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Cefalotin | Cefalotin may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Cefamandole | Cefamandole may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Cefapirin | Cefapirin may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Cefazolin | Cefazolin may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Cefdinir | Leuprolide may decrease the excretion rate of Cefdinir which could result in a higher serum level. |
| Cefditoren | Cefditoren may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Cefepime | Cefepime may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Cefmenoxime | Cefmenoxime may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Cefmetazole | Cefmetazole may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Cefonicid | Cefonicid may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Cefoperazone | Cefoperazone may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Ceforanide | Ceforanide may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Cefotaxime | Cefotaxime may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Cefotetan | Cefotetan may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Cefotiam | Cefotiam may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Cefoxitin | Cefoxitin may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Cefpiramide | Cefpiramide may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Cefpirome | Cefpirome may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Cefpodoxime | Cefpodoxime may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Cefprozil | Cefprozil may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Cefradine | Cefradine may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Ceftaroline fosamil | Ceftaroline fosamil may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Ceftazidime | Ceftazidime may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Ceftibuten | Ceftibuten may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Ceftizoxime | Ceftizoxime may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Ceftobiprole | Ceftobiprole may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Ceftolozane | Leuprolide may decrease the excretion rate of Ceftolozane which could result in a higher serum level. |
| Ceftriaxone | Ceftriaxone may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Cefuroxime | Cefuroxime may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Celecoxib | Celecoxib may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Celiprolol | The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Leuprolide. |
| Cephalexin | Cephalexin may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Cephaloglycin | Cephaloglycin may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Ceritinib | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ceritinib. |
| Cerivastatin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Cerivastatin. |
| Certolizumab p | Leuprolide may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level. |
| Cetirizine | The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Leuprolide. |
| Cevimeline | Leuprolide may decrease the excretion rate of Cevimeline which could result in a higher serum level. |
| Chloral hydrate | Leuprolide may decrease the excretion rate of Chloral hydrate which could result in a higher serum level. |
| Chlorcyclizine | The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Leuprolide. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Chloroprocaine. |
| Chloroquine | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Chloroquine. |
| Chlorothiazide | Chlorothiazide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Chlorpheniramine | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Chlorpheniramine. |
| Chlorpromazine | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Chlorpromazine. |
| Chlorpropamide | The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Leuprolide. |
| Chlorprothixene | The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Leuprolide. |
| Chlorthalidone | Chlorthalidone may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Chlorzoxazone | Leuprolide may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level. |
| Choline C 11 | Leuprolide may decrease effectiveness of Choline C 11 as a diagnostic agent. |
| Choline magnesium | Choline magnesium trisalicylate may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Choline salicylate | Leuprolide may decrease the excretion rate of Choline salicylate which could result in a higher serum level. |
| Chondroitin sulfate | Leuprolide may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level. |
| Chromic chloride | Leuprolide may decrease the excretion rate of Chromic chloride which could result in a higher serum level. |
| Chromic nitrate | Leuprolide may decrease the excretion rate of Chromic nitrate which could result in a higher serum level. |
| Chromium | Leuprolide may decrease the excretion rate of Chromium which could result in a higher serum level. |
| Chromium gluconate | Leuprolide may decrease the excretion rate of Chromium gluconate which could result in a higher serum level. |
| Chromium nicoti | Leuprolide may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level. |
| Chromous sulfate | Leuprolide may decrease the excretion rate of Chromous sulfate which could result in a higher serum level. |
| Cidofovir | Cidofovir may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Cilostazol | The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Leuprolide. |
| Cimetidine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Cimetidine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Cinchocaine. |
| Cinnarizine | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Cinnarizine. |
| Cinoxacin | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Cinoxacin. |
| Ciprofibrate | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Ciprofibrate. |
| Ciprofloxacin | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ciprofloxacin. |
| Cisapride | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Cisapride. |
| Cisplatin | Leuprolide may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Citalopram | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Citalopram. |
| Cladribine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Cladribine. |
| Clarithromycin | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Clarithromycin. |
| Clemastine | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Clemastine. |
| Clevidipine | Leuprolide may decrease the excretion rate of Clevidipine which could result in a higher serum level. |
| Clobazam | Leuprolide may decrease the excretion rate of Clobazam which could result in a higher serum level. |
| Clofarabine | Leuprolide may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Clofazimine | The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Leuprolide. |
| Clofibrate | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Clofibrate. |
| Clomipramine | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Clomipramine. |
| Clonazepam | Leuprolide may decrease the excretion rate of Clonazepam which could result in a higher serum level. |
| Clorazepic acid | Leuprolide may decrease the excretion rate of Clorazepic acid which could result in a higher serum level. |
| Clove oil | Leuprolide may decrease the excretion rate of Clove oil which could result in a higher serum level. |
| Clozapine | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Clozapine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Cocaine. |
| Colchicine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Colchicine. |
| Colistimethate | Colistimethate may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Colistin | Leuprolide may decrease the excretion rate of Colistin which could result in a higher serum level. |
| Conivaptan | Conivaptan may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Conjugated estro | Leuprolide may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level. |
| Corifollitropin a | The therapeutic efficacy of Corifollitropin alfa can be increased when used in combination with Leuprolide. |
| Crizotinib | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Crizotinib. |
| Cyanocobalamin | Leuprolide may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level. |
| Cyclizine | The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Leuprolide. |
| Cyclopenthiazide | Cyclopenthiazide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Cyclosporine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Cyclosporine. |
| Cyclothiazide | Cyclothiazide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Cyproheptadine | The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Leuprolide. |
| Cytarabine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Cytarabine. |
| Dabigatran etexi | Leuprolide may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level. |
| Dabrafenib | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Leuprolide. |
| Dacarbazine | Leuprolide may decrease the excretion rate of Dacarbazine which could result in a higher serum level. |
| Dalfampridine | Leuprolide may decrease the excretion rate of Dalfampridine which could result in a higher serum level. |
| Dapagliflozin | The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Leuprolide. |
| Daptomycin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Daptomycin. |
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Leuprolide. |
| Dasatinib | The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Leuprolide. |
| Deferiprone | Leuprolide may decrease the excretion rate of Deferiprone which could result in a higher serum level. |
| Degarelix | The risk or severity of QTc prolongation can be increased when Degarelix is combined with Leuprolide. |
| Delafloxacin | The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Leuprolide. |
| Delamanid | Leuprolide may increase the QTc-prolonging activities of Delamanid. |
| Desflurane | The risk or severity of QTc prolongation can be increased when Desflurane is combined with Leuprolide. |
| Desipramine | The risk or severity of QTc prolongation can be increased when Desipramine is combined with Leuprolide. |
| Desloratadine | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Desloratadine. |
| Desmopressin | Leuprolide may decrease the excretion rate of Desmopressin which could result in a higher serum level. |
| Desvenlafaxine | Leuprolide may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level. |
| Deutetrabenazine | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Deutetrabenazine. |
| Dexamethasone | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Dexamethasone. |
| Dexbrompheniramine | The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Leuprolide. |
| Dexchlorpheniramine | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Dexchlorpheniramine maleate. |
| Dexibuprofen | Dexibuprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Dexketoprofen | Dexketoprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Dexmedetomidine | Leuprolide may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level. |
| Dexpanthenol | Leuprolide may decrease the excretion rate of Dexpanthenol which could result in a higher serum level. |
| Dexrazoxane | Leuprolide may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
| Dextran | Leuprolide may decrease the excretion rate of Dextran which could result in a higher serum level. |
| Diatrizoate | Leuprolide may decrease the excretion rate of Diatrizoate which could result in a higher serum level. |
| Diazepam | Leuprolide may decrease the excretion rate of Diazepam which could result in a higher serum level. |
| Dichlorobenzyl alcohol | Leuprolide may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level. |
| Diclofenac | Diclofenac may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Diclofenamide | Diclofenamide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Dicyclomine | Leuprolide may decrease the excretion rate of Dicyclomine which could result in a higher serum level. |
| Didanosine | Leuprolide may decrease the excretion rate of Didanosine which could result in a higher serum level. |
| Dienogest | Leuprolide may decrease the excretion rate of Dienogest which could result in a higher serum level. |
| Diflunisal | Diflunisal may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Difluocortolone | Leuprolide may decrease the excretion rate of Difluocortolone which could result in a higher serum level. |
| Digitoxin | The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Leuprolide. |
| Digoxin | Leuprolide may decrease the excretion rate of Digoxin which could result in a higher serum level. |
| Dihydrostreptomycin | Dihydrostreptomycin may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Diltiazem | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Diltiazem. |
| Dimenhydrinate | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Dimenhydrinate. |
| Dimercaprol | Leuprolide may decrease the excretion rate of Dimercaprol which could result in a higher serum level. |
| Dimethyl sulfoxide | Leuprolide may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Diphenhydramine. |
| Disopyramide | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Disopyramide. |
| Disulfiram | The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Leuprolide. |
| DL-Methylephedrine | Leuprolide may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level. |
| Dobutamine | Leuprolide may decrease the excretion rate of Dobutamine which could result in a higher serum level. |
| Docetaxel | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Docetaxel. |
| Dofetilide | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Dofetilide. |
| Dolasetron | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Dolasetron. |
| Domperidone | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Domperidone. |
| Dopamine | Leuprolide may decrease the excretion rate of Dopamine which could result in a higher serum level. |
| Doripenem | Leuprolide may decrease the excretion rate of Doripenem which could result in a higher serum level. |
| Dosulepin | The risk or severity of QTc prolongation can be increased when Dosulepin is combined with Leuprolide. |
| Doxacurium | Leuprolide may decrease the excretion rate of Doxacurium which could result in a higher serum level. |
| Doxepin | The risk or severity of QTc prolongation can be increased when Doxepin is combined with Leuprolide. |
| Doxycycline | Leuprolide may decrease the excretion rate of Doxycycline which could result in a higher serum level. |
| Doxylamine | The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Leuprolide. |
| Dronedarone | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Dronedarone. |
| Droperidol | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Droperidol. |
| Drospirenone | Drospirenone may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Droxidopa | Leuprolide may decrease the excretion rate of Droxidopa which could result in a higher serum level. |
| Dulaglutide | The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Leuprolide. |
| Duloxetine | Leuprolide may decrease the excretion rate of Duloxetine which could result in a higher serum level. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Dyclonine. |
| Dyphylline | Leuprolide may decrease the excretion rate of Dyphylline which could result in a higher serum level. |
| Ebastine | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Leuprolide. |
| Edoxaban | Leuprolide may decrease the excretion rate of Edoxaban which could result in a higher serum level. |
| Edrophonium | Leuprolide may decrease the excretion rate of Edrophonium which could result in a higher serum level. |
| Efavirenz | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Efavirenz. |
| Eliglustat | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Eliglustat. |
| Emedastine | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Emedastine. |
| Empagliflozin | The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Leuprolide. |
| Enalapril | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Enalapril. |
| Enalaprilat | Leuprolide may decrease the excretion rate of Enalaprilat which could result in a higher serum level. |
| Encainide | The risk or severity of QTc prolongation can be increased when Encainide is combined with Leuprolide. |
| Encorafenib | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Encorafenib. |
| Enoxacin | The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Leuprolide. |
| Entrectinib | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Entrectinib. |
| Enzalutamide | Leuprolide may decrease the excretion rate of Enzalutamide which could result in a higher serum level. |
| Epinastine | The risk or severity of QTc prolongation can be increased when Epinastine is combined with Leuprolide. |
| Eplerenone | Eplerenone may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Epoprostenol | Leuprolide may decrease the excretion rate of Epoprostenol which could result in a higher serum level. |
| Eprosartan | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Eprosartan. |
| Eribulin | The risk or severity of QTc prolongation can be increased when Eribulin is combined with Leuprolide. |
| Erlotinib | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Erlotinib. |
| Ertapenem | Leuprolide may decrease the excretion rate of Ertapenem which could result in a higher serum level. |
| Ertugliflozin | The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Leuprolide. |
| Erythromycin | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Erythromycin. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Leuprolide. |
| Escitalopram | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Escitalopram. |
| Esmolol | The risk or severity of QTc prolongation can be increased when Esmolol is combined with Leuprolide. |
| Estazolam | Leuprolide may decrease the excretion rate of Estazolam which could result in a higher serum level. |
| Estradiol | Leuprolide may decrease the excretion rate of Estradiol which could result in a higher serum level. |
| Estradiol acetate | Leuprolide may decrease the excretion rate of Estradiol acetate which could result in a higher serum level. |
| Estradiol cypionate | Leuprolide may decrease the excretion rate of Estradiol cypionate which could result in a higher serum level. |
| Estradiol dienanthate | Leuprolide may decrease the excretion rate of Estradiol dienanthate which could result in a higher serum level. |
| Estradiol valerate | Leuprolide may decrease the excretion rate of Estradiol valerate which could result in a higher serum level. |
| Estrone sulfate | Leuprolide may decrease the excretion rate of Estrone sulfate which could result in a higher serum level. |
| Eszopiclone | Leuprolide may decrease the excretion rate of Eszopiclone which could result in a higher serum level. |
| Etacrynic acid | Etacrynic acid may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Etafedrine | Leuprolide may decrease the excretion rate of Etafedrine which could result in a higher serum level. |
| Ethambutol | Leuprolide may decrease the excretion rate of Ethambutol which could result in a higher serum level. |
| Ethanol | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Ethanol. |
| Ethosuximide | The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Leuprolide. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Ethyl chloride. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Etidocaine. |
| Etodolac | Etodolac may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Etomidate | Leuprolide may decrease the excretion rate of Etomidate which could result in a higher serum level. |
| Etonogestrel | Leuprolide may decrease the excretion rate of Etonogestrel which could result in a higher serum level. |
| Etoricoxib | Etoricoxib may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Eucalyptus oil | Leuprolide may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level. |
| Exenatide | The therapeutic efficacy of Exenatide can be decreased when used in combination with Leuprolide. |
| Ezogabine | The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Leuprolide. |
| Famotidine | The risk or severity of QTc prolongation can be increased when Famotidine is combined with Leuprolide. |
| Felbamate | The risk or severity of QTc prolongation can be increased when Felbamate is combined with Leuprolide. |
| Felodipine | The risk or severity of QTc prolongation can be increased when Felodipine is combined with Leuprolide. |
| Fenbufen | Fenbufen may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Fenofibrate | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Fenofibrate. |
| Fenofibric acid | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Fenofibric acid. |
| Fenoldopam | Leuprolide may decrease the excretion rate of Fenoldopam which could result in a higher serum level. |
| Fenoprofen | Fenoprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Fentanyl | Leuprolide may decrease the excretion rate of Fentanyl which could result in a higher serum level. |
| Fesoterodine | Leuprolide may decrease the excretion rate of Fesoterodine which could result in a higher serum level. |
| Fexinidazole | The risk or severity of adverse effects can be increased when Leuprolide is combined with Fexinidazole. |
| Finerenone | Finerenone may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Flavoxate | Leuprolide may decrease the excretion rate of Flavoxate which could result in a higher serum level. |
| Flecainide | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Flecainide. |
| Floctafenine | Floctafenine may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Florbetaben (18F) | Leuprolide may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level. |
| Florbetapir (18F) | Leuprolide may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level. |
| Floxuridine | Leuprolide may decrease the excretion rate of Floxuridine which could result in a higher serum level. |
| Fluconazole | The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Leuprolide. |
| Flucytosine | Leuprolide may decrease the excretion rate of Flucytosine which could result in a higher serum level. |
| Fludeoxyglucose | Leuprolide may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level. |
| Flumazenil | Leuprolide may decrease the excretion rate of Flumazenil which could result in a higher serum level. |
| Fluocinolone acetonide | Leuprolide may decrease the excretion rate of Fluocinolone acetonide which could result in a higher serum level. |
| Fluorouracil | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Fluorouracil. |
| Fluoxetine | The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Leuprolide. |
| Flupentixol | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Flupentixol. |
| Flurazepam | Leuprolide may decrease the excretion rate of Flurazepam which could result in a higher serum level. |
| Flurbiprofen | Flurbiprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Fluspirilene | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Fluspirilene. |
| Flutamide | Leuprolide may decrease the excretion rate of Flutamide which could result in a higher serum level. |
| Fluvastatin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Fluvastatin. |
| Fluvoxamine | Leuprolide may decrease the excretion rate of Fluvoxamine which could result in a higher serum level. |
| Folic acid | Leuprolide may decrease the excretion rate of Folic acid which could result in a higher serum level. |
| Fomepizole | Leuprolide may decrease the excretion rate of Fomepizole which could result in a higher serum level. |
| Fondaparinux | Leuprolide may decrease the excretion rate of Fondaparinux which could result in a higher serum level. |
| Formestane | Leuprolide may decrease the excretion rate of Formestane which could result in a higher serum level. |
| Formoterol | The risk or severity of QTc prolongation can be increased when Formoterol is combined with Leuprolide. |
| Foscarnet | The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Leuprolide. |
| Fosfomycin | Leuprolide may decrease the excretion rate of Fosfomycin which could result in a higher serum level. |
| Fosinopril | Leuprolide may decrease the excretion rate of Fosinopril which could result in a higher serum level. |
| Fostemsavir | The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Leuprolide. |
| Framycetin | Framycetin may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Furosemide | Furosemide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Fusidic acid | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Fusidic acid. |
| Gabapentin enacar | Leuprolide may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level. |
| Gadobenic acid | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Gadobenic acid. |
| Gadodiamide | Leuprolide may decrease the excretion rate of Gadodiamide which could result in a higher serum level. |
| Gadofosveset trisodium | Leuprolide may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level. |
| Gadopentetic acid | Leuprolide may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level. |
| Gadoteric acid | Leuprolide may decrease the excretion rate of Gadoteric acid which could result in a higher serum level. |
| Gadoteridol | Leuprolide may decrease the excretion rate of Gadoteridol which could result in a higher serum level. |
| Galantamine | The risk or severity of QTc prolongation can be increased when Galantamine is combined with Leuprolide. |
| Ganciclovir | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Ganciclovir. |
| Gatifloxacin | The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Leuprolide. |
| Gemcitabine | Leuprolide may decrease the excretion rate of Gemcitabine which could result in a higher serum level. |
| Gemfibrozil | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Gemfibrozil. |
| Gemifloxacin | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Gemifloxacin. |
| Gentamicin | Leuprolide may decrease the excretion rate of Gentamicin which could result in a higher serum level. |
| Gilteritinib | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Gilteritinib. |
| Gimeracil | Leuprolide may decrease the excretion rate of Gimeracil which could result in a higher serum level. |
| Givosiran | Givosiran may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Glasdegib | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Glasdegib. |
| Gliclazide | The therapeutic efficacy of Gliclazide can be decreased when used in combination with Leuprolide. |
| Glimepiride | The therapeutic efficacy of Glimepiride can be decreased when used in combination with Leuprolide. |
| Glipizide | The therapeutic efficacy of Glipizide can be decreased when used in combination with Leuprolide. |
| Gliquidone | The therapeutic efficacy of Gliquidone can be decreased when used in combination with Leuprolide. |
| Glyburide | The therapeutic efficacy of Glyburide can be decreased when used in combination with Leuprolide. |
| Glycerol phenyl | Leuprolide may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level. |
| Glymidine | The therapeutic efficacy of Glymidine can be decreased when used in combination with Leuprolide. |
| Golodirsen | Leuprolide may decrease the excretion rate of Golodirsen which could result in a higher serum level. |
| Goserelin | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Goserelin. |
| Granisetron | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Granisetron. |
| Grepafloxacin | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Grepafloxacin. |
| Guanethidine | Leuprolide may decrease the excretion rate of Guanethidine which could result in a higher serum level. |
| Guanfacine | Leuprolide may decrease the excretion rate of Guanfacine which could result in a higher serum level. |
| Halofantrine | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Halofantrine. |
| Haloperidol | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Haloperidol. |
| Histrelin | The risk or severity of QTc prolongation can be increased when Histrelin is combined with Leuprolide. |
| Hydralazine | Leuprolide may decrease the excretion rate of Hydralazine which could result in a higher serum level. |
| Hydrochlorothiazide | Hydrochlorothiazide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Hydroflumethiazide | Hydroflumethiazide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Hydromorphone | Leuprolide may decrease the excretion rate of Hydromorphone which could result in a higher serum level. |
| Hydroxocobalamin | Leuprolide may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level. |
| Hydroxychloroquine | The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Leuprolide. |
| Hydroxyethyl Starch | Leuprolide may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level. |
| Hydroxyzine | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Hydroxyzine. |
| Hyoscyamine | The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Leuprolide. |
| Ibandronate | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Ibandronate. |
| Ibuprofen | Ibuprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Ibutilide | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ibutilide. |
| Icatibant | Leuprolide may decrease the excretion rate of Icatibant which could result in a higher serum level. |
| Icosapent | Icosapent may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Idarucizumab | Leuprolide may decrease the excretion rate of Idarucizumab which could result in a higher serum level. |
| Idebenone | Leuprolide may decrease the excretion rate of Idebenone which could result in a higher serum level. |
| Ifosfamide | Leuprolide may decrease the excretion rate of Ifosfamide which could result in a higher serum level. |
| Iloperidone | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Iloperidone. |
| Iloprost | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Iloprost. |
| Imatinib | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Imatinib. |
| Imipramine | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Imipramine. |
| Indacaterol | The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Leuprolide. |
| Indapamide | Indapamide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Indigotindisulfonic | Leuprolide may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level. |
| Indinavir | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Indinavir. |
| Indomethacin | Indomethacin may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Infliximab | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Infliximab. |
| Inosine pranobex | Leuprolide may decrease the excretion rate of Inosine pranobex which could result in a higher serum level. |
| Inositol | Leuprolide may decrease the excretion rate of Inositol which could result in a higher serum level. |
| Inotersen | The risk or severity of QTc prolongation can be increased when Inotersen is combined with Leuprolide. |
| Insulin aspart | The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Leuprolide. |
| Insulin beef | The therapeutic efficacy of Insulin beef can be decreased when used in combination with Leuprolide. |
| Insulin degludec | The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Leuprolide. |
| Insulin detemir | The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Leuprolide. |
| Insulin glargine | The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Leuprolide. |
| Insulin glulisine | The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Leuprolide. |
| Insulin human | The therapeutic efficacy of Insulin human can be decreased when used in combination with Leuprolide. |
| Insulin lispro | The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Leuprolide. |
| Insulin pork | The therapeutic efficacy of Insulin pork can be decreased when used in combination with Leuprolide. |
| Iobenguane sulfate | Leuprolide may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level. |
| Iodixanol | Leuprolide may decrease the excretion rate of Iodixanol which could result in a higher serum level. |
| Ioflupane I-123 | Leuprolide may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level. |
| Iopromide | Leuprolide may decrease the excretion rate of Iopromide which could result in a higher serum level. |
| Iothalamic acid | Leuprolide may decrease the excretion rate of Iothalamic acid which could result in a higher serum level. |
| Ioversol | Leuprolide may decrease the excretion rate of Ioversol which could result in a higher serum level. |
| Ioxilan | Leuprolide may decrease the excretion rate of Ioxilan which could result in a higher serum level. |
| Ipecac | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Ipecac. |
| Ipilimumab | Leuprolide may decrease the excretion rate of Ipilimumab which could result in a higher serum level. |
| Isoflurane | The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Leuprolide. |
| Isoniazid | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Isoniazid. |
| Isosorbide | Isosorbide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Isosorbide monon | Leuprolide may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level. |
| Isosulfan blue | Leuprolide may decrease the excretion rate of Isosulfan blue which could result in a higher serum level. |
| Isotretinoin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Isotretinoin. |
| Isoxicam | Isoxicam may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Isradipine | The risk or severity of QTc prolongation can be increased when Isradipine is combined with Leuprolide. |
| Itraconazole | The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Leuprolide. |
| Ivabradine | Ivabradine may increase the QTc-prolonging activities of Leuprolide. |
| Ivermectin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Ivermectin. |
| Ivosidenib | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ivosidenib. |
| Ixazomib | Leuprolide may decrease the excretion rate of Ixazomib which could result in a higher serum level. |
| Kanamycin | Leuprolide may decrease the excretion rate of Kanamycin which could result in a higher serum level. |
| Ketamine | Leuprolide may decrease the excretion rate of Ketamine which could result in a higher serum level. |
| Ketazolam | Leuprolide may decrease the excretion rate of Ketazolam which could result in a higher serum level. |
| Ketoconazole | The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Leuprolide. |
| Ketoprofen | Ketoprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Ketorolac | Ketorolac may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Labetalol | Leuprolide may decrease the excretion rate of Labetalol which could result in a higher serum level. |
| Lacidipine | The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Leuprolide. |
| Lamivudine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Lamivudine. |
| Lamotrigine | The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Leuprolide. |
| Lapatinib | The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Leuprolide. |
| Latamoxef | Latamoxef may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Ledipasvir | Leuprolide may decrease the excretion rate of Ledipasvir which could result in a higher serum level. |
| Lefamulin | Lefamulin may increase the QTc-prolonging activities of Leuprolide. |
| Leflunomide | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Leflunomide. |
| Lenalidomide | Leuprolide may decrease the excretion rate of Lenalidomide which could result in a higher serum level. |
| Lenvatinib | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Lenvatinib. |
| Lercanidipine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Lercanidipine. |
| Lesinurad | Leuprolide may decrease the excretion rate of Lesinurad which could result in a higher serum level. |
| Letrozole | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Letrozole. |
| Levacetylmethadol | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Levacetylmethadol. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Levobupivacaine. |
| Levocabastine | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Leuprolide. |
| Levocarnitine | Leuprolide may decrease the excretion rate of Levocarnitine which could result in a higher serum level. |
| Levocetirizine | The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Leuprolide. |
| Levofloxacin | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Levofloxacin. |
| Levomenthol | The risk or severity of QTc prolongation can be increased when Levomenthol is combined with Leuprolide. |
| Levomilnacipran | Leuprolide may decrease the excretion rate of Levomilnacipran which could result in a higher serum level. |
| Levosalbutamol | Leuprolide may decrease the excretion rate of Levosalbutamol which could result in a higher serum level. |
| Levosimendan | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Levosimendan. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Lidocaine. |
| Lidoflazine | The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Leuprolide. |
| Linagliptin | The therapeutic efficacy of Linagliptin can be decreased when used in combination with Leuprolide. |
| Liothyronine | Leuprolide may decrease the excretion rate of Liothyronine which could result in a higher serum level. |
| Liraglutide | The therapeutic efficacy of Liraglutide can be decreased when used in combination with Leuprolide. |
| Lisinopril | Leuprolide may decrease the excretion rate of Lisinopril which could result in a higher serum level. |
| Lithium carbonate | Leuprolide may decrease the excretion rate of Lithium carbonate which could result in a higher serum level. |
| Lithium citrate | Lithium citrate may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Lixisenatide | The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Leuprolide. |
| Lofexidine | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Lofexidine. |
| Lomefloxacin | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Lomefloxacin. |
| Loperamide | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Loperamide. |
| Lopinavir | The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Leuprolide. |
| Loracarbef | Loracarbef may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Lorazepam | Leuprolide may decrease the excretion rate of Lorazepam which could result in a higher serum level. |
| Lorcaserin | Leuprolide may decrease the excretion rate of Lorcaserin which could result in a higher serum level. |
| Lornoxicam | Lornoxicam may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Lorpiprazole | Leuprolide may decrease the excretion rate of Lorpiprazole which could result in a higher serum level. |
| Losartan | The risk or severity of QTc prolongation can be increased when Losartan is combined with Leuprolide. |
| Lovastatin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Lovastatin. |
| Loxoprofen | Loxoprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Lubiprostone | Leuprolide may decrease the excretion rate of Lubiprostone which could result in a higher serum level. |
| Lumefantrine | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Lumefantrine. |
| Lumiracoxib | Lumiracoxib may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Lurasidone | The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Leuprolide. |
| Macimorelin | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Macimorelin. |
| Macitentan | Leuprolide may decrease the excretion rate of Macitentan which could result in a higher serum level. |
| Magnesium carbo | Leuprolide may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level. |
| Magnesium chloride | Leuprolide may decrease the excretion rate of Magnesium chloride which could result in a higher serum level. |
| Magnesium hydr | Leuprolide may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level. |
| Magnesium trisil | Leuprolide may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level. |
| Mangafodipir | Leuprolide may decrease the excretion rate of Mangafodipir which could result in a higher serum level. |
| Mannitol | Mannitol may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Maprotiline | The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Leuprolide. |
| Mebeverine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Mebeverine. |
| Mecamylamine | Leuprolide may decrease the excretion rate of Mecamylamine which could result in a higher serum level. |
| Mecasermin | The therapeutic efficacy of Mecasermin can be decreased when used in combination with Leuprolide. |
| Meclofenamic | Meclofenamic acid may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Medroxyprogestero | Leuprolide may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level. |
| Mefenamic acid | Mefenamic acid may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Mefloquine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Mefloquine. |
| Megestrol acetate | Leuprolide may decrease the excretion rate of Megestrol acetate which could result in a higher serum level. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Meloxicam. |
| Memantine | Leuprolide may decrease the excretion rate of Memantine which could result in a higher serum level. |
| Meperidine | Leuprolide may decrease the excretion rate of Meperidine which could result in a higher serum level. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Mepivacaine. |
| Mepyramine | The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Leuprolide. |
| Meropenem | Leuprolide may decrease the excretion rate of Meropenem which could result in a higher serum level. |
| Mesalazine | Mesalazine may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Mesoridazine | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Mesoridazine. |
| Metamfetamine | Leuprolide may decrease the excretion rate of Metamfetamine which could result in a higher serum level. |
| Metamizole | Metamizole may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Metaxalone | Leuprolide may decrease the excretion rate of Metaxalone which could result in a higher serum level. |
| Metformin | The therapeutic efficacy of Metformin can be decreased when used in combination with Leuprolide. |
| Methadone | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Methadone. |
| Methazolamide | Methazolamide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Methimazole | Leuprolide may decrease the excretion rate of Methimazole which could result in a higher serum level. |
| Methotrexate | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Methotrexate. |
| Methotrimeprazine | The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Leuprolide. |
| Methoxsalen | Leuprolide may decrease the excretion rate of Methoxsalen which could result in a higher serum level. |
| Methoxy po | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Leuprolide. |
| Methsuximide | The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Leuprolide. |
| Methyldopa | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Methyldopa. |
| Methylene blue | Leuprolide may decrease the excretion rate of Methylene blue which could result in a higher serum level. |
| Methylnaltrexone | Leuprolide may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level. |
| Methyltestosterone | Leuprolide may decrease the excretion rate of Methyltestosterone which could result in a higher serum level. |
| Meticrane | Meticrane may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Metoclopramide | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Metoclopramide. |
| Metolazone | Metolazone may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Metoprolol | Leuprolide may decrease the excretion rate of Metoprolol which could result in a higher serum level. |
| Metronidazole | The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Leuprolide. |
| Metyrapone | Leuprolide may decrease the excretion rate of Metyrapone which could result in a higher serum level. |
| Midazolam | Leuprolide may decrease the excretion rate of Midazolam which could result in a higher serum level. |
| Mifepristone | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Mifepristone. |
| Migalastat | Leuprolide may decrease the excretion rate of Migalastat which could result in a higher serum level. |
| Miglitol | The therapeutic efficacy of Miglitol can be decreased when used in combination with Leuprolide. |
| Milnacipran | Leuprolide may decrease the excretion rate of Milnacipran which could result in a higher serum level. |
| Milrinone | Leuprolide may decrease the excretion rate of Milrinone which could result in a higher serum level. |
| Minocycline | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Minocycline. |
| Mirabegron | The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Leuprolide. |
| Mirtazapine | The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Leuprolide. |
| Mizolastine | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Mizolastine. |
| Mobocertinib | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Mobocertinib. |
| Moexipril | The risk or severity of QTc prolongation can be increased when Moexipril is combined with Leuprolide. |
| Montelukast | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Montelukast. |
| Moricizine | The risk or severity of QTc prolongation can be increased when Moricizine is combined with Leuprolide. |
| Moxifloxacin | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Moxifloxacin. |
| Moxisylyte | Leuprolide may decrease the excretion rate of Moxisylyte which could result in a higher serum level. |
| Muzolimine | Muzolimine may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Mycophenolate | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Mycophenolate mofetil. |
| Mycophenolic acid | Leuprolide may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level. |
| N-acetyltyrosine | Leuprolide may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level. |
| Nabumetone | Nabumetone may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Nadolol | Leuprolide may decrease the excretion rate of Nadolol which could result in a higher serum level. |
| Nafarelin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Nafarelin. |
| Naldemedine | Leuprolide may decrease the excretion rate of Naldemedine which could result in a higher serum level. |
| Nalidixic acid | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Nalidixic acid. |
| Nalmefene | Leuprolide may decrease the excretion rate of Nalmefene which could result in a higher serum level. |
| Naloxone | Leuprolide may decrease the excretion rate of Naloxone which could result in a higher serum level. |
| Naltrexone | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Naltrexone. |
| Naproxen | Naproxen may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Nateglinide | The therapeutic efficacy of Nateglinide can be decreased when used in combination with Leuprolide. |
| Nedaplatin | Leuprolide may decrease the excretion rate of Nedaplatin which could result in a higher serum level. |
| Nedocromil | Leuprolide may decrease the excretion rate of Nedocromil which could result in a higher serum level. |
| Nefazodone | Leuprolide may decrease the excretion rate of Nefazodone which could result in a higher serum level. |
| Nelfinavir | The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Leuprolide. |
| Neomycin | Leuprolide may decrease the excretion rate of Neomycin which could result in a higher serum level. |
| Netilmicin | Leuprolide may decrease the excretion rate of Netilmicin which could result in a higher serum level. |
| Niacin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Niacin. |
| Nicardipine | The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Leuprolide. |
| Nicorandil | Leuprolide may decrease the excretion rate of Nicorandil which could result in a higher serum level. |
| Nifedipine | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Nifedipine. |
| Nilotinib | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Nilotinib. |
| Nilutamide | Leuprolide may decrease the excretion rate of Nilutamide which could result in a higher serum level. |
| Nilvadipine | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Nilvadipine. |
| Nimesulide | Nimesulide may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Nimodipine | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Nimodipine. |
| Nisoldipine | Leuprolide may decrease the excretion rate of Nisoldipine which could result in a higher serum level. |
| Nitrendipine | The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Leuprolide. |
| Nitric Oxide | Leuprolide may decrease the excretion rate of Nitric Oxide which could result in a higher serum level. |
| Nitrofurantoin | Leuprolide may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level. |
| Nitroprusside | Leuprolide may decrease the excretion rate of Nitroprusside which could result in a higher serum level. |
| Nizatidine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Nizatidine. |
| Norfloxacin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Norfloxacin. |
| Nortriptyline | The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Leuprolide. |
| Octinoxate | Leuprolide may decrease the excretion rate of Octinoxate which could result in a higher serum level. |
| Octreotide | The risk or severity of QTc prolongation can be increased when Octreotide is combined with Leuprolide. |
| Ofloxacin | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ofloxacin. |
| Olanzapine | The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Leuprolide. |
| Olodaterol | The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Leuprolide. |
| Olsalazine | Olsalazine may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Ondansetron | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ondansetron. |
| Opium | Leuprolide may decrease the excretion rate of Opium which could result in a higher serum level. |
| Orphenadrine | The risk or severity of QTc prolongation can be increased when Orphenadrine is combined with Leuprolide. |
| Oseltamivir | Leuprolide may decrease the excretion rate of Oseltamivir which could result in a higher serum level. |
| Oxacillin | Leuprolide may decrease the excretion rate of Oxacillin which could result in a higher serum level. |
| Oxaliplatin | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Oxaliplatin. |
| Oxaprozin | Oxaprozin may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Oxatomide | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Oxatomide. |
| Oxazepam | Leuprolide may decrease the excretion rate of Oxazepam which could result in a higher serum level. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Oxetacaine. |
| Oxybenzone | Leuprolide may decrease the excretion rate of Oxybenzone which could result in a higher serum level. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Oxybuprocaine. |
| Oxyphenbutazone | Oxyphenbutazone may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Oxyquinoline | Leuprolide may decrease the excretion rate of Oxyquinoline which could result in a higher serum level. |
| Oxytocin | The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Leuprolide. |
| Paclitaxel | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Paclitaxel. |
| Pacritinib | The risk or severity of QTc prolongation can be increased when Pacritinib is combined with Leuprolide. |
| Paliperidone | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Paliperidone. |
| Palonosetron | Leuprolide may decrease the excretion rate of Palonosetron which could result in a higher serum level. |
| Pamidronic acid | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Pamidronic acid. |
| Panobinostat | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Panobinostat. |
| Pantoprazole | Leuprolide may decrease the excretion rate of Pantoprazole which could result in a higher serum level. |
| Papaverine | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Papaverine. |
| Parecoxib | Parecoxib may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Paromomycin | Paromomycin may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Pasireotide | The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Leuprolide. |
| Patent Blue | Leuprolide may decrease the excretion rate of Patent Blue which could result in a higher serum level. |
| Pazopanib | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Pazopanib. |
| Pefloxacin | The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Leuprolide. |
| Pegaptanib | Leuprolide may decrease the excretion rate of Pegaptanib which could result in a higher serum level. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Leuprolide. |
| Pemetrexed | Leuprolide may decrease the excretion rate of Pemetrexed which could result in a higher serum level. |
| Penbutolol | Leuprolide may decrease the excretion rate of Penbutolol which could result in a higher serum level. |
| Penicillamine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Penicillamine. |
| Pentaerythritol t | Leuprolide may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level. |
| Pentamidine | The therapeutic efficacy of Pentamidine can be decreased when used in combination with Leuprolide. |
| Pentastarch | Leuprolide may decrease the excretion rate of Pentastarch which could result in a higher serum level. |
| Pentetic acid | Leuprolide may decrease the excretion rate of Pentetic acid which could result in a higher serum level. |
| Pentobarbital | Leuprolide may decrease the excretion rate of Pentobarbital which could result in a higher serum level. |
| Pentostatin | Leuprolide may decrease the excretion rate of Pentostatin which could result in a higher serum level. |
| Pentoxifylline | Leuprolide may decrease the excretion rate of Pentoxifylline which could result in a higher serum level. |
| Perflutren | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Perflutren. |
| Perhexiline | The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Leuprolide. |
| Perindopril | Leuprolide may decrease the excretion rate of Perindopril which could result in a higher serum level. |
| Permethrin | Leuprolide may decrease the excretion rate of Permethrin which could result in a higher serum level. |
| Phenazopyridine | Phenazopyridine may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Phenelzine | Leuprolide may decrease the excretion rate of Phenelzine which could result in a higher serum level. |
| Phenformin | The therapeutic efficacy of Phenformin can be decreased when used in combination with Leuprolide. |
| Pheniramine | The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Leuprolide. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Phenol. |
| Phentolamine | Leuprolide may decrease the excretion rate of Phentolamine which could result in a higher serum level. |
| Phenylbutazone | Phenylbutazone may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Phenytoin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Phenytoin. |
| Pholcodine | Leuprolide may decrease the excretion rate of Pholcodine which could result in a higher serum level. |
| Phosphoric acid | Leuprolide may decrease the excretion rate of Phosphoric acid which could result in a higher serum level. |
| Phylloquinone | Leuprolide may decrease the excretion rate of Phylloquinone which could result in a higher serum level. |
| Picosulfuric acid | Leuprolide may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level. |
| Pimozide | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Pimozide. |
| Pinaverium | The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Leuprolide. |
| Pindolol | Leuprolide may decrease the excretion rate of Pindolol which could result in a higher serum level. |
| Pioglitazone | The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Leuprolide. |
| Piperacillin | Leuprolide may decrease the excretion rate of Piperacillin which could result in a higher serum level. |
| Piracetam | Leuprolide may decrease the excretion rate of Piracetam which could result in a higher serum level. |
| Piretanide | Piretanide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Piroxicam | Piroxicam may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Pitavastatin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Pitavastatin. |
| Pitolisant | Leuprolide may increase the QTc-prolonging activities of Pitolisant. |
| Plazomicin | Leuprolide may decrease the excretion rate of Plazomicin which could result in a higher serum level. |
| Plerixafor | Leuprolide may decrease the excretion rate of Plerixafor which could result in a higher serum level. |
| Polythiazide | Polythiazide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Pomalidomide | Leuprolide may decrease the excretion rate of Pomalidomide which could result in a higher serum level. |
| Ponesimod | The risk or severity of bradycardia can be increased when Ponesimod is combined with Leuprolide. |
| Posaconazole | The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Leuprolide. |
| Potassium | Potassium may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Potassium acetate | Leuprolide may decrease the excretion rate of Potassium acetate which could result in a higher serum level. |
| Potassium bicar | Leuprolide may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level. |
| Potassium cation | Potassium cation may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Potassium chloride | Leuprolide may decrease the excretion rate of Potassium chloride which could result in a higher serum level. |
| Potassium citrate | Potassium citrate may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Potassium nitrate | Leuprolide may decrease the excretion rate of Potassium nitrate which could result in a higher serum level. |
| Potassium perchlo | Leuprolide may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level. |
| Potassium sulfate | Leuprolide may decrease the excretion rate of Potassium sulfate which could result in a higher serum level. |
| Pralatrexate | Leuprolide may decrease the excretion rate of Pralatrexate which could result in a higher serum level. |
| Pralidoxime | Leuprolide may decrease the excretion rate of Pralidoxime which could result in a higher serum level. |
| Pramipexole | Leuprolide may decrease the excretion rate of Pramipexole which could result in a higher serum level. |
| Pramlintide | The therapeutic efficacy of Pramlintide can be decreased when used in combination with Leuprolide. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Pramocaine. |
| Prasugrel | Leuprolide may decrease the excretion rate of Prasugrel which could result in a higher serum level. |
| Pravastatin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Pravastatin. |
| Prednisone | Leuprolide may decrease the excretion rate of Prednisone which could result in a higher serum level. |
| Pregabalin | The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Leuprolide. |
| Prenylamine | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Prenylamine. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Prilocaine. |
| Primaquine | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Primaquine. |
| Probenecid | Leuprolide may decrease the excretion rate of Probenecid which could result in a higher serum level. |
| Probucol | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Probucol. |
| Procainamide | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Procainamide. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Procaine. |
| Procaine benzylp | Leuprolide may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level. |
| Procarbazine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Procarbazine. |
| Prochlorperazine | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Prochlorperazine. |
| Promazine | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Promazine. |
| Promethazine | The risk or severity of QTc prolongation can be increased when Promethazine is combined with Leuprolide. |
| Propafenone | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Propafenone. |
| Propantheline | Leuprolide may decrease the excretion rate of Propantheline which could result in a higher serum level. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Proparacaine. |
| Propiverine | Leuprolide may decrease the excretion rate of Propiverine which could result in a higher serum level. |
| Propofol | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Propofol. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Propoxycaine. |
| Propranolol | Leuprolide may decrease the excretion rate of Propranolol which could result in a higher serum level. |
| Propylthiouracil | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Propylthiouracil. |
| Protriptyline | The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Leuprolide. |
| Prucalopride | Leuprolide may decrease the excretion rate of Prucalopride which could result in a higher serum level. |
| Pyrantel | Leuprolide may decrease the excretion rate of Pyrantel which could result in a higher serum level. |
| Pyrazinamide | Leuprolide may decrease the excretion rate of Pyrazinamide which could result in a higher serum level. |
| Pyridoxine | Leuprolide may decrease the excretion rate of Pyridoxine which could result in a higher serum level. |
| Quetiapine | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Quetiapine. |
| Quinethazone | Quinethazone may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Quinidine | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Quinidine. |
| Quinine | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Quinine. |
| Rabeprazole | Leuprolide may decrease the excretion rate of Rabeprazole which could result in a higher serum level. |
| Raltegravir | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Raltegravir. |
| Ramelteon | Leuprolide may decrease the excretion rate of Ramelteon which could result in a higher serum level. |
| Ranitidine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Ranitidine. |
| Ranolazine | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ranolazine. |
| Rasagiline | Leuprolide may decrease the excretion rate of Rasagiline which could result in a higher serum level. |
| Relugolix | The risk or severity of QTc prolongation can be increased when Relugolix is combined with Leuprolide. |
| Repaglinide | The therapeutic efficacy of Repaglinide can be decreased when used in combination with Leuprolide. |
| Reserpine | Leuprolide may decrease the excretion rate of Reserpine which could result in a higher serum level. |
| Resorcinol | Leuprolide may decrease the excretion rate of Resorcinol which could result in a higher serum level. |
| Ribavirin | Leuprolide may decrease the excretion rate of Ribavirin which could result in a higher serum level. |
| Ribociclib | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ribociclib. |
| Ribostamycin | Leuprolide may decrease the excretion rate of Ribostamycin which could result in a higher serum level. |
| Rilpivirine | The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Leuprolide. |
| Risedronic acid | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Risedronic acid. |
| Risperidone | The risk or severity of QTc prolongation can be increased when Risperidone is combined with Leuprolide. |
| Ritonavir | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Ritonavir. |
| Rivaroxaban | Leuprolide may decrease the excretion rate of Rivaroxaban which could result in a higher serum level. |
| Rizatriptan | Leuprolide may decrease the excretion rate of Rizatriptan which could result in a higher serum level. |
| Rofecoxib | Rofecoxib may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Roflumilast | Leuprolide may decrease the excretion rate of Roflumilast which could result in a higher serum level. |
| Romidepsin | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Romidepsin. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Ropivacaine. |
| Rosiglitazone | The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Leuprolide. |
| Rosoxacin | The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Leuprolide. |
| Rosuvastatin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Rosuvastatin. |
| Roxithromycin | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Roxithromycin. |
| Rupatadine | The risk or severity of QTc prolongation can be increased when Rupatadine is combined with Leuprolide. |
| Ruxolitinib | Leuprolide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level. |
| Sacubitril | Leuprolide may decrease the excretion rate of Sacubitril which could result in a higher serum level. |
| Salbutamol | The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Leuprolide. |
| Salicylamide | Salicylamide may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Salicylic acid | Salicylic acid may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Salmeterol | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Salmeterol. |
| Salmon calcit | Leuprolide may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level. |
| Salsalate | Salsalate may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Saquinavir | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Saquinavir. |
| Saxagliptin | The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Leuprolide. |
| Secobarbital | Leuprolide may decrease the excretion rate of Secobarbital which could result in a higher serum level. |
| Selenious acid | Leuprolide may decrease the excretion rate of Selenious acid which could result in a higher serum level. |
| Selenium | Leuprolide may decrease the excretion rate of Selenium which could result in a higher serum level. |
| Semaglutide | The therapeutic efficacy of Semaglutide can be decreased when used in combination with Leuprolide. |
| Sevoflurane | The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Leuprolide. |
| Sibutramine | Leuprolide may decrease the excretion rate of Sibutramine which could result in a higher serum level. |
| Sildenafil | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Sildenafil. |
| Simvastatin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Simvastatin. |
| Sitagliptin | The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Leuprolide. |
| Sodium acetate | Leuprolide may decrease the excretion rate of Sodium acetate which could result in a higher serum level. |
| Sodium aurothi | Leuprolide may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level. |
| Sodium fluoride | Leuprolide may decrease the excretion rate of Sodium fluoride which could result in a higher serum level. |
| Sodium sulfate | Leuprolide may decrease the excretion rate of Sodium sulfate which could result in a higher serum level. |
| Sofosbuvir | Leuprolide may decrease the excretion rate of Sofosbuvir which could result in a higher serum level. |
| Solifenacin | The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Leuprolide. |
| Solriamfetol | Leuprolide may decrease the excretion rate of Solriamfetol which could result in a higher serum level. |
| Somatotropin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Somatotropin. |
| Sorafenib | The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Leuprolide. |
| Sorbitol | Leuprolide may decrease the excretion rate of Sorbitol which could result in a higher serum level. |
| Sotagliflozin | The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Leuprolide. |
| Sotalol | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Sotalol. |
| Sparfloxacin | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Sparfloxacin. |
| Spironolactone | Spironolactone may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Stavudine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Stavudine. |
| Stiripentol | Leuprolide may decrease the excretion rate of Stiripentol which could result in a higher serum level. |
| Streptomycin | Leuprolide may decrease the excretion rate of Streptomycin which could result in a higher serum level. |
| Strontium chloride | Leuprolide may decrease the excretion rate of Strontium chloride which could result in a higher serum level. |
| Sucralfate | Leuprolide may decrease the excretion rate of Sucralfate which could result in a higher serum level. |
| Sulbactam | Leuprolide may decrease the excretion rate of Sulbactam which could result in a higher serum level. |
| Sulfadiazine | The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Leuprolide. |
| Sulfamethoxazole | The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Leuprolide. |
| Sulfasalazine | Sulfasalazine may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Sulfisoxazole | The therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Leuprolide. |
| Sulindac | Sulindac may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Sulpiride | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Sulpiride. |
| Sultopride | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Sultopride. |
| Sumatriptan | Leuprolide may decrease the excretion rate of Sumatriptan which could result in a higher serum level. |
| Sunitinib | The therapeutic efficacy of Sunitinib can be decreased when used in combination with Leuprolide. |
| Sy Estrogens, A | Leuprolide may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level. |
| Synt Estrogens, B | Leuprolide may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level. |
| Tacrine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Tacrine. |
| Tacrolimus | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Tacrolimus. |
| Tadalafil | Leuprolide may decrease the excretion rate of Tadalafil which could result in a higher serum level. |
| Tamoxifen | The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Leuprolide. |
| Tamsulosin | Leuprolide may decrease the excretion rate of Tamsulosin which could result in a higher serum level. |
| Tasimelteon | Leuprolide may decrease the excretion rate of Tasimelteon which could result in a higher serum level. |
| Technetium | Leuprolide may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level. |
| Technetium Tc | Leuprolide may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level. |
| Technetium Tc | Leuprolide may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level. |
| Technetium Tc | Leuprolide may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level. |
| Teduglutide | Leuprolide may decrease the excretion rate of Teduglutide which could result in a higher serum level. |
| Tegafur | Leuprolide may decrease the excretion rate of Tegafur which could result in a higher serum level. |
| Telavancin | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Telavancin. |
| Telithromycin | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Telithromycin. |
| Temazepam | Leuprolide may decrease the excretion rate of Temazepam which could result in a higher serum level. |
| Temozolomide | Leuprolide may decrease the excretion rate of Temozolomide which could result in a higher serum level. |
| Tenofovir alafen | The serum concentration of Tenofovir alafenamide can be increased when it is combined with Leuprolide. |
| Tenofovir disop | Tenofovir disoproxil may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Tenoxicam | Tenoxicam may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Terbinafine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Terbinafine. |
| Terbutaline | The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Leuprolide. |
| Terfenadine | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Terfenadine. |
| Terlipressin | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Terlipressin. |
| Testolactone | Leuprolide may decrease the excretion rate of Testolactone which could result in a higher serum level. |
| Testosterone | Leuprolide may decrease the excretion rate of Testosterone which could result in a higher serum level. |
| Testosterone cypi | Leuprolide may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level. |
| Testosterone enan | Leuprolide may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level. |
| Testosterone prop | Leuprolide may decrease the excretion rate of Testosterone propionate which could result in a higher serum level. |
| Testosterone und | Leuprolide may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level. |
| Tetrabenazine | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Tetrabenazine. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Tetracaine. |
| Tetracycline | Leuprolide may decrease the excretion rate of Tetracycline which could result in a higher serum level. |
| Tetradecyl hydrog | Leuprolide may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level. |
| Thiabendazole | Leuprolide may decrease the excretion rate of Thiabendazole which could result in a higher serum level. |
| Thiethylperazine | Leuprolide may decrease the excretion rate of Thiethylperazine which could result in a higher serum level. |
| Thioridazine | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Thioridazine. |
| Thiothixene | The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Leuprolide. |
| Tiaprofenic acid | Tiaprofenic acid may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Ticlopidine | Leuprolide may decrease the excretion rate of Ticlopidine which could result in a higher serum level. |
| Tiludronic acid | Leuprolide may decrease the excretion rate of Tiludronic acid which could result in a higher serum level. |
| Timolol | The risk or severity of QTc prolongation can be increased when Timolol is combined with Leuprolide. |
| Tinidazole | Leuprolide may decrease the excretion rate of Tinidazole which could result in a higher serum level. |
| Tiopronin | Leuprolide may decrease the excretion rate of Tiopronin which could result in a higher serum level. |
| Tiotropium | Leuprolide may decrease the excretion rate of Tiotropium which could result in a higher serum level. |
| Tirofiban | Leuprolide may decrease the excretion rate of Tirofiban which could result in a higher serum level. |
| Tirzepatide | The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Leuprolide. |
| Tixocortol | Leuprolide may decrease the excretion rate of Tixocortol which could result in a higher serum level. |
| Tizanidine | The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Leuprolide. |
| Tobramycin | Leuprolide may decrease the excretion rate of Tobramycin which could result in a higher serum level. |
| Tocopherol | Leuprolide may decrease the excretion rate of Tocopherol which could result in a higher serum level. |
| Tolazamide | The therapeutic efficacy of Tolazamide can be decreased when used in combination with Leuprolide. |
| Tolbutamide | The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Leuprolide. |
| Tolcapone | Leuprolide may decrease the excretion rate of Tolcapone which could result in a higher serum level. |
| Tolfenamic acid | Tolfenamic acid may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Tolmetin | Tolmetin may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Tolterodine | The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Leuprolide. |
| Tolvaptan | Tolvaptan may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Topiramate | Leuprolide may decrease the excretion rate of Topiramate which could result in a higher serum level. |
| Topotecan | Leuprolide may decrease the excretion rate of Topotecan which could result in a higher serum level. |
| Torasemide | Torasemide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Toremifene | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Toremifene. |
| Tositumomab | Leuprolide may decrease the excretion rate of Tositumomab which could result in a higher serum level. |
| Trabectedin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Trabectedin. |
| Tramadol | Leuprolide may decrease the excretion rate of Tramadol which could result in a higher serum level. |
| Trametinib | Leuprolide may decrease the excretion rate of Trametinib which could result in a higher serum level. |
| Trazodone | The risk or severity of QTc prolongation can be increased when Trazodone is combined with Leuprolide. |
| Treprostinil | The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Leuprolide. |
| Triamcinolone | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Triamcinolone. |
| Triamterene | Triamterene may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Triazolam | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Triazolam. |
| Trichlormethiazide | Trichlormethiazide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Triclabendazole | The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Leuprolide. |
| Triethylenetetram | Leuprolide may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level. |
| Trifluridine | Leuprolide may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Trimebutine | The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Leuprolide. |
| Trimethadione | The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Leuprolide. |
| Trimethoprim | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Trimethoprim. |
| Trimetrexate | Leuprolide may decrease the excretion rate of Trimetrexate which could result in a higher serum level. |
| Trimipramine | The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Leuprolide. |
| Triprolidine | The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Leuprolide. |
| Triptorelin | The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Leuprolide. |
| Troglitazone | The therapeutic efficacy of Troglitazone can be decreased when used in combination with Leuprolide. |
| Tropisetron | Leuprolide may decrease the excretion rate of Tropisetron which could result in a higher serum level. |
| Trovafloxacin | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Trovafloxacin. |
| Ubidecarenone | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Ubidecarenone. |
| Vaborbactam | Leuprolide may decrease the excretion rate of Vaborbactam which could result in a higher serum level. |
| Valaciclovir | Valaciclovir may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Valbenazine | Leuprolide may decrease the excretion rate of Valbenazine which could result in a higher serum level. |
| Valdecoxib | Valdecoxib may decrease the excretion rate of Leuprolide which could result in a higher serum level. |
| Valganciclovir | Leuprolide may decrease the excretion rate of Valganciclovir which could result in a higher serum level. |
| Valproic acid | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Valproic acid. |
| Vancomycin | Leuprolide may decrease the excretion rate of Vancomycin which could result in a higher serum level. |
| Vandetanib | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Vandetanib. |
| Vardenafil | The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Leuprolide. |
| Varenicline | Leuprolide may decrease the excretion rate of Varenicline which could result in a higher serum level. |
| Vemurafenib | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Vemurafenib. |
| Venlafaxine | Leuprolide may decrease the excretion rate of Venlafaxine which could result in a higher serum level. |
| Verapamil | Leuprolide may decrease the excretion rate of Verapamil which could result in a higher serum level. |
| Vernakalant | The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Leuprolide. |
| Vilanterol | The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Leuprolide. |
| Vildagliptin | The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Leuprolide. |
| Viloxazine | Leuprolide may decrease the excretion rate of Viloxazine which could result in a higher serum level. |
| Vincristine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Vincristine. |
| Voriconazole | The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Leuprolide. |
| Vorinostat | The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Leuprolide. |
| Vortioxetine | Leuprolide may decrease the excretion rate of Vortioxetine which could result in a higher serum level. |
| Warfarin | Leuprolide may decrease the excretion rate of Warfarin which could result in a higher serum level. |
| Zaleplon | Leuprolide may decrease the excretion rate of Zaleplon which could result in a higher serum level. |
| Zanamivir | Leuprolide may decrease the excretion rate of Zanamivir which could result in a higher serum level. |
| Zidovudine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Zidovudine. |
| Ziprasidone | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ziprasidone. |
| Zonisamide | Zonisamide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Zuclopenthixol | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Zuclopenthixol. |
Pregnancy and Lactation
US FDA pregnancy category: Not assigned.
Pregnancy
The effects on fetal mortality are expected consequences of the alterations in hormonal levels brought about by this drug. Therefore, the possibility exists that spontaneous abortion may occur if the drug is administered during pregnancy. If this drug is administered during pregnancy or if the patient becomes pregnant while taking any formulation of leuprolide acetate, the patient should be apprised of the potential hazard to the fetus
Lactation
Nursing Mothers: It is not known whether leuprolide acetate is excreted in human milk. Leuprolide acetate should not be used by nursing mothers.
Why is this medication prescribed?
Leuprolide injection (Eligard, Lupron Depot) is used to treat the symptoms associated with advanced prostate cancer. Leuprolide injection (Lupron Depot-PED, Fensolvi) is used in children 2 years of age or older to treat central precocious puberty (CPP; a condition causing girls [usually younger than 8 years of age] and boys [usually younger than 9 years of age] to enter puberty too soon, resulting in faster than normal bone growth and development of sexual characteristics). Leuprolide injection (Lupron Depot) is used alone or with another medication (norethindrone) to treat endometriosis (a condition in which the type of tissue that lines the uterus [womb] grows in other areas of the body and causes pain, heavy or irregular menstruation [periods], and other symptoms). Leuprolide injection (Lupron Depot) is also used with other medication to treat anemia (a lower-than-normal number of red blood cells) caused by uterine fibroids (noncancerous growths in the uterus). Leuprolide injection is in a class of medications called gonadotropin-releasing hormone (GnRH) agonists. It works by decreasing the number of certain hormones in the body.
How should this medicine be used?
Leuprolide injection comes as a long-acting suspension (Lupron) that is injected intramuscularly (into a muscle) by a doctor or nurse in a medical office or clinic and is usually given once a month (Lupron Depot, Lupron Depot-PED) or every 3, 4, or 6 months (Lupron Depot-3 month, Lupron Depot-PED-3 month, Lupron Depot-4 month, Lupron Depot-6 Month). Leuprolide injection also comes as a long-acting suspension (Eligard) that is injected subcutaneously (just under the skin) by a doctor or nurse in a medical office or clinic and is usually given every 1, 3, 4, or 6 months. Leuprolide injection also comes as a long-acting suspension (Fensolvi) that is injected subcutaneously (just under the skin) by a doctor or nurse in a medical office or clinic and is usually given every 6 months. Your doctor will tell you how long your treatment with leuprolide injection will last. When used in children with precocious puberty, leuprolide injection (Lupron Depot-PED, Lupron Depot-PED-3 month, Fensolvi) will likely be stopped by your child’s doctor before 11 years of age in girls and 12 years of age in boys.
If you receive leuprolide long-acting suspension (Eligard) as a subcutaneous injection, you may notice a small bump at the place where the injection was given when you first receive the medication. This bump should eventually go away.
Leuprolide may cause an increase in certain hormones in the first few weeks after injection. Your doctor will monitor you carefully for any new or worsening symptoms during this time. Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient. This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.
What special precautions should I follow?
Before receiving a leuprolide injection,
- tell your doctor and pharmacist if you are allergic to leuprolide, goserelin (Zoladex), histrelin (Supprelin LA, Vantas), nafarelin (Synarel), triptorelin (Triptodur, Trelstar), any other medications, or any of the ingredients in leuprolide injection. Ask your pharmacist for a list of the ingredients.
- tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: certain medications for irregular heartbeat such as amiodarone (Cordarone), disopyramide (Norpace), procainamide (Procanbid), quinidine, and sotalol (Betapace, Betapace AF, Sorine); bupropion (Aplenzin, Forfivo, Wellbutrin, in Contrave); medications for seizures; oral steroids such as dexamethasone (Hemady), methylprednisolone (Medrol), and prednisone (Rayos); and selective serotonin reuptake inhibitors (SSRIs) such as citalopram (Celexa), escitalopram (Lexapro), fluoxetine (Prozac, Sarafem, in Symbyax), fluvoxamine (Luvox), paroxetine (Brisdelle, Paxil), and sertraline (Zoloft). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with leuprolide, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
- tell your doctor if you have unusual vaginal bleeding. Your doctor may tell you not to use leuprolide injection.
- tell your doctor if you or anyone in your family has or has ever had osteoporosis (a condition where bones are thin and more likely to break); if you have a history of drinking alcohol or using tobacco products for a long period of time; or if you have or have ever had depression, seizures, brain tumors, cancer that has spread to the spine (backbone), diabetes, urinary obstruction (blockage that causes difficulty urinating), blood in your urine, a prolonged QT interval (a rare heart problem that may cause irregular heartbeat, fainting, or sudden death), cerebrovascular disease (clogging or weakening of the blood vessels within the brain or leading to the brain), heart disease, or a low level of potassium, calcium, or magnesium in your blood.
- you should know that leuprolide is not to be used in women who are pregnant, can become pregnant, or are breastfeeding. Tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. Your doctor may perform a pregnancy test to be sure that you are not pregnant when you begin receiving leuprolide injections. You will need to use a reliable nonhormonal method of birth control to prevent pregnancy while you are receiving a leuprolide injection. Talk to your doctor about the types of birth control that are right for you, and continue to use birth control even though you should not have regular menstrual periods during your treatment. If you think you have become pregnant while receiving a leuprolide injection, call your doctor immediately. Leuprolide injection can harm the fetus.
